NEW YORK, July 14, 2017 /PRNewswire/ --
If you want a Stock Review on OSUR, XRAY, BAX or GKOS then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. Changing demographics, healthcare reform, and product innovation will shape the Medical Instruments and Supplies industry in the coming years, according to an IBISWorld report. The aging population is
On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 1.06 million shares, which was above their three months average volume of 856,880 shares. The stock ended the session 0.53% higher at $18.81. The Company's shares have surged 22.70% in the last one month, 52.55% over the previous three months, and 114.24% on an YTD basis. The stock is trading 20.38% above its 50-day moving average and 68.28% above its 200-day moving average. Moreover, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 74.28.
On July 12th, 2017, OraSure Technologies announced that it has scheduled its regular earnings conference call covering Q2 2017 financial results, Q3 2017 financial guidance, and certain business developments on August 02nd, 2017, at 5:00 p.m. ET. The conference call will be webcast live, and may be accessed under the Investor Relations page of the Company's website. The free research report on OSUR is available at:
York, Pennsylvania headquartered DENTSPLY SIRONA Inc.'s stock closed the day 0.76% higher at $64.89 with a total trading volume of 773,549 shares. The Company's shares have advanced 2.54% in the past month, 4.68% in the previous three months, and 12.40% since the start of this year. The stock is trading 2.06% and 6.54% above its 50-day and 200-day moving averages, respectively. Additionally, shares of DENTSPLY SIRONA, which designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide, have an RSI of 58.79.
On June 28th, 2017, DENTSPLY SIRONA announced that its Board of Directors declared a quarterly cash dividend of $0.0875 per share of common stock, an indicated annual rate of $0.35 per share. The dividend is payable on October 13th, 2017 to holders of record on September 29th, 2017.
On July 11th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $74 per share. The complimentary report on XRAY can be downloaded at:
Shares in Deerfield, Illinois headquartered Baxter International Inc. recorded a trading volume of 1.74 million shares. The stock ended yesterday's trading session 0.03% higher at $61.30. The Company's shares have advanced 5.91% in the past month, 14.52% in the previous three months, and 38.25% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.44% and 20.17%, respectively. Furthermore, shares of Baxter, which provides a portfolio of renal and hospital products, have an RSI of 63.38.
On June 29th, 2017, Baxter announced that it will host a conference call on July 26th, 2017, at 7:30 a.m. CT to discuss its Q2 2017 financial results. The call will be webcast and will be accessible on the Company's website. Visit us today and download our complete research report on BAX for free at:
San Clemente, California headquartered Glaukos Corp.'s stock finished Thursday's session 0.52% lower at $39.79 with a total trading volume of 347,286 shares. The Company's shares have advanced 16.01% since the start of this year. The stock is trading below its 200-day moving average by 1.17%. Additionally, shares of Glaukos, which focuses on the development and commercialization of products and procedures designed to treat glaucoma, have an RSI of 44.28.
On June 21st, 2017, Glaukos announced that a study of 53 open-angle glaucoma subjects recently published in Clinical & Experimental Ophthalmology showed that the iStent inject® Trabecular Micro-Bypass, combined with topical travoprost, delivered a 35% reduction in mean intraocular pressure (IOP) to 12.9 mm Hg after 18 months of follow-up. The results of the study underscore the viability of using iStent inject, together with a single postoperative prostaglandin medication, to consistently manage IOP to levels in the 15 mm Hg range. Get free access to your technical report on GKOS at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All